Dr. Peltz founded PTC Therapeutics in 1998 and has served as CEO and a member of the Board of Directors since the company’s inception. Under his leadership, PTC has grown from a research organization into a global, publicly traded, fully-integrated biotech company with multiple approved products. PTC’s hallmark is its deep commitment to science, employing multiple technology platforms to drive a robust discovery pipeline in support of Patients with rare disorders around the world.

Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in the field. Dr. Peltz was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVOICE’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision, Innovation and Leadership in 2014.

Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.